Tyr625
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr625  -  CAPN2 (human)

Site Information
RSGtMNSyEMRkALE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 3413522

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
brain cancer ( 2 ) , glioblastoma ( 2 ) , glioma ( 2 ) , liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Src (human) ( 1 )
Treatments:
dasatinib ( 1 )

Downstream Regulation
Effects of modification on CAPN2:
enzymatic activity, induced ( 1 )
Effects of modification on biological processes:
carcinogenesis, induced ( 1 ) , cell growth, inhibited ( 1 )

References 

1

Ma XL, et al. (2022) Identification of a novel Calpain-2-SRC feed-back loop as necessity for β-Catenin accumulation and signaling activation in hepatocellular carcinoma. Oncogene 41, 3554-3569
35697802   Curated Info

2

Stokes M (2006) CST Curation Set: 1447; Year: 2006; Biosample/Treatment: cell line, H4/serum starved; Disease: glioma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info